https://www.healthcaretribunefrance.com/article/914318521-cancer-vaccines-market-to-witness-massive-growth-by-2033-neovax-bio-celluvax-inc Healthcare Tribune France en PressRelease 2026-05-22T11:41:51+00:00 Cancer Vaccines Market to Witness Massive Growth by 2033 | NeoVax Bio, CelluVax Inc. https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24864507-cancer-vaccines-market-1024x1024.jpeg https://www.healthcaretribunefrance.com/article/914437169-abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-trial-of Healthcare Tribune France en PressRelease 2026-05-22T20:05:00+00:00 Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.healthcaretribunefrance.com/article/914437171-abivax-pr-sente-ses-r-sultats-financiers-du-t1-2026-et-les-donn-es-trois-ans-de-l-tude-108-un-essai-d-extension-ouvert-de-phase-2a-2b-valuant Healthcare Tribune France en PressRelease 2026-05-22T20:05:00+00:00 Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/ https://www.healthcaretribunefrance.com/article/914131234-kfsh-calls-for-scaling-ai-from-pilots-to-patient-impact-at-world-economic-forum-health-roundtable Healthcare Tribune France en PressRelease 2026-05-21T21:12:57+00:00 KFSH Calls for Scaling AI from Pilots to Patient Impact at World Economic Forum Health Roundtable https://www.healthcaretribunefrance.com/article/914005716-kfsh-spotlights-ai-s-role-in-expanding-patient-access-while-preserving-human-centered-care Healthcare Tribune France en PressRelease 2026-05-21T08:39:50+00:00 KFSH Spotlights AI’s Role in Expanding Patient Access While Preserving Human-Centered Care https://www.healthcaretribunefrance.com/article/914127350-inventiva-to-present-at-2026-jefferies-global-healthcare-conference Healthcare Tribune France en PressRelease 2026-05-21T20:00:00+00:00 Inventiva to Present at 2026 Jefferies Global Healthcare Conference   https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/logo-iva-jpg.jpg https://www.healthcaretribunefrance.com/article/914127354-inventiva-pr-sentera-lors-de-la-2026-jefferies-global-healthcare-conference Healthcare Tribune France en PressRelease 2026-05-21T20:00:00+00:00 Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference https://ml-eu.globenewswire.com/media/d96e203b-8941-46c7-888a-508900ab9a8b/small/ https://www.healthcaretribunefrance.com/article/914127557-oddifact-obtient-la-d-signation-m-dicament-orphelin-de-la-commission-europ-enne-pour-l-infliximab-dans-la-maladie-de-kawasaki Healthcare Tribune France en PressRelease 2026-05-21T18:50:22+00:00 ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki https://ml-eu.globenewswire.com/media/e678baea-021e-47f5-9676-4ef415772a73/small/ https://www.healthcaretribunefrance.com/article/914127755-oddifact-receives-european-commission-orphan-drug-designation-for-infliximab-in-kawasaki-disease Healthcare Tribune France en PressRelease 2026-05-21T18:50:22+00:00 ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease https://ml-eu.globenewswire.com/media/e678baea-021e-47f5-9676-4ef415772a73/small/logo-oddifact-png.png https://www.healthcaretribunefrance.com/article/914040604-edap-focal-one-to-present-at-jefferies-2026-global-healthcare-conference Healthcare Tribune France en PressRelease 2026-05-21T11:30:00+00:00 EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference https://ml-eu.globenewswire.com/media/ded19329-9645-4860-ac2d-bf3e2422b649/small/focalone-square-logo-drkblue-web-400-1-png.png